We evaluated the clinical effects of intravenously administered secretin in 12 children with autism (age range: 4–6 years, median age: 9 years, boy:girl=8:4). In addition, we investigated the association between improvement in symptoms and changes in the cerebrospinal fluid (CSF) homovanillic acid (HVA),5-hydroxyindole-3-acetic acid (5-HIAA), and 6R-5,6,7,8-tetrahydro-L-biopterin (BH4) levels after administration. After administration of secretin, the Autism Diagnostic Interview-Revised (ADI-R) score improved in 7 of the 12 children. However, the score deteriorated in 2 of the 12 children (in the item of ‘restricted and repetitive, stereotyped interests and behaviors’). The HVA and BH4 levels in CSF were increased in all children with improvement in the ADI-R score. In contrast, no patient without the elevation of the BH4 level showed improvement in the score. These findings suggest that secretin activated metabolic turnover of dopamine in the central nervous system via BH4, improving symptoms.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Brain and Development
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- A neurological model of infantile autism (in Japanese).No No Kagaku (Tokyo). 1998; 20: 169-175
- A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder.Arch Gen Psychiatry. 1996; 53: 1001-1008
- Improved social and language skills after secretin administration in patients with autistic spectrum disorders.J Assoc Acad Minor Phys. 1998; 9: 9-15
- Metabolic changes in aromatic amino acids and monoamines in infantile autism and development of new treatment related to the finding (in Japanese).No To Hattatsu. 1989; 21: 181-189
- Possible effects of tetrahydrobiopterin treatment in six children with autism—clinical and positron emission tomography data: a pilot study.Dev Med Child Neurol. 1997; 39: 313-318
- Cerebrospinal fluid biopterin and biogenic amine metabolites during oral R-THBP therapy for infantile autism.J Autism Dev Disord. 1995; 25: 183-193
- Disorder of tetrahydrobiopterin and related biogenic amines.in: Scriver C.R. Beaudet A.L. Sly W. Valle D. Childs B. Kinzler K.W. Vogelstein B. The metabolic and molecular bases of inherited disease. McGraw Hill, London2000: 1725-1776
- Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder.N Engl J Med. 1999; 341: 1801-1806
- Effects of intravenous secretin on language and behavior of children with autism and gastrointestinal symptoms: a single-blinded, open-label pilot study.Pediatrics. 2001; 108: E90
- Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions.Endocrinology. 1994; 135: 2662-2680
- Secretin and vasoactive intestinal peptide activate tyrosine hydroxylase in sympathetic nerve endings.J Neurosci. 1989; 9: 160-166
Accepted: May 25, 2005
Received in revised form: May 25, 2005
Received: October 20, 2004
© 2005 Elsevier B.V. Published by Elsevier Inc. All rights reserved.